Description of Research Expertise:
My research is dedicated to improving treatment outcomes of patients with HIV and tuberculosis (TB) and other AIDS-associated opportunistic infections. Current research projects are evaluating the relationship between very early virologic and immunologic response to antiretroviral therapy and clinical outcomes in adults with HIV/TB. Many patients with advanced HIV die soon after antiretroviral therapy initiation, and our research group focuses on trying to understand the pathophysiologic and social mechanisms underlying these early deaths. In addition, we are pursuing translational projects evaluating novel host-directed therapies for treatment of drug resistant TB.
Selected Publications:
Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C: Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study J Antimicrob Chemother : pii: dkz265,2019.
Ravimohan S, Auld SC, Maenetje P, Ratsela N, Mlotshwa M, Ncube I, Smith JP, Vangu M-D-T, Sebe M, Kossenkov A, Weissman D, Wallis RS, Churchyard G, Kornfeld H, Bisson GP: Lung injury on antiretroviral therapy in adults with HIV/TB Clin Infect Dis : pii: ciz560,2019.
Torgersen J, Bellamy SL, Ratshaa B, Han X, Mosepele M, Zuppa AF, Vujkovic M, Steenhoff AP, Bisson GP, Gross R: Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans Eur J Drug Metab Pharmacokinet 44 (2): 179-187,2019.
Jarvis JN, Leeme TB, Molefi M, Chofle AA, Bidwell G, Tsholo K, Tlhako N, Mawoko N, Patel RKK, Tenforde MW, Muthoga C, Bisson GP, Kidola J, Changalucha J, Lawrence D, Jaffar S, Hope W, Molloy SLF, Harrison TS: Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial Clin Infect Dis 68 (3): 393-401,2019.
Sereti Irini, Bisson Gregory P, Meintjes Graeme Ayton (Eds): HIV and Tuberculosis: A Formidable Alliance Springer International Publishing : 2019.
Auld SC, Maenetje P, Ravimohan S, Weissman D, Ncube I, Mlotshawa M, Ratsela N, Chase W, Vangu MDI-T, Wallis R, Churchyard G, Kornfeld H, Bisson GP: Declines in Lung Function after ART initiation in Adults with HIV and TB: A Potential Manifestation of Respiratory IRIS Clin Infect Dis : 2019.
Ravimohan S, Maenetje P, Auld SC, Ncube I, Mlotshwa M, Chase W, Tiemessen CT, Vangu MdT, Wallis R, Churchyard G, Weissman D, Kornfeld H, Bisson GP: A common NLRC4 gene variant associates with inflammation and pulmonary function in HIV/TB Clin Infect Dis : 2019.
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan P-C, Chan ED, Chang K-C, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Holtz TH: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis Lancet 392 (10150): 821-834,2018.
Vujkovic M, Bellamy S, Zuppa A, Gastonguay M, Moorthy G, Ratshaa B, Han X, Steenhoff A, Mosepele M, Strom B, Bisson GP, Aplenc R, Gross R: Polymorphisms in Cytochrome P450 are associated with Extensive Efavirenz Pharmacokinetics and CNS Toxicities in an HIV Cohort in Botswana Pharmacogenomics J 18 (5): 678-688,2018.
Ngongondo M, Miyahara S, Hughes M, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg J, Torres T, Nyirenda M, Kidonge K, Hosseinpour C, AIDS Clinical Trials Group A5274 (REMEMBER) Study Team: Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial J Acquir Immune Defic Syndr 78 (1): 54-61,2018.